subscribeSubscribe
Edoxaban Noninferior to Warfarin in Atrial Fibrillation After TAVI

Edoxaban Noninferior to Warfarin in Atrial Fibrillation After TAVI
ESCARDIO
01 Sep 2021
Share Share
Warfarin use significantly increases risk of knee and hip replacement

Warfarin use significantly increases risk of knee and hip replacement
EUREKALERT
10 Nov 2020
Share Share
Portola`s Announces Results Andexxa was Associated with Lowest Rate of Mortality

Portola`s Announces Results Andexxa was Associated with Lowest Rate of Mortality
PR NEWSWIRE
16 Mar 2020
Share Share
XARELTO Reduced the Risk of Strokes in Nonvalvular Atrial Fibrillation

XARELTO Reduced the Risk of Strokes in Nonvalvular Atrial Fibrillation
PR NEWSWIRE
18 Mar 2019
Share Share
Cereno Scientific driving thrombosis prevention without bleeding-risks

Cereno Scientific driving thrombosis prevention without bleeding-risks
Jonas Söderström ENDPTS
06 Dec 2018
Share Share
Increased use of anti-clotting drugs tied to fewer strokes in Afib

Increased use of anti-clotting drugs tied to fewer strokes in Afib
Lisa Rapaport REUTERS
25 Sep 2018
Share Share
EMA advices Armetheon to conduct single 1000 patients study for tecarfarin

EMA advices Armetheon to conduct single 1000 patients study for tecarfarin
PHARMABIZ
16 Feb 2017
Share Share
INRatio Blood Monitoring Device Recalled Due to Inaccurate Readings

INRatio Blood Monitoring Device Recalled Due to Inaccurate Readings
NEWSINFERNO
24 Jan 2017
Share Share
J&J clot fighter battles Pfizer/Bristol for warfarin

J&J clot fighter battles Pfizer/Bristol for warfarin
Carly Helfand FIERCE PHARMA
26 Oct 2016
Share Share
Boehringer Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Boehringer Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)
PR NEWSWIRE
23 Mar 2016
Share Share